The Pro-FEIBA Study

The Pro-FEIBA Study was an investigator-initiated prospective, multicentre, randomised, crossover arm trial conducted at 16 haemophilia treatment centres in Europe and the United States.

It compared 6 months of FEIBA prophylaxis with 6 months of on-demand therapy in 34 patients. Patients were ≥ 2 years of age with haemophilia A and a history of high-titre FVIII inhibitors, and with ≥ 6 bleeding episodes requiring bypassing therapy in the 6 months prior to enrolment.

At the conclusion of the study, 26 patients were evaluable per protocol.

The results of the Pro-FEIBA study add significantly to the existing evidence for FEIBA prophylaxis.

Learn about the PROOF Study >>

Learn about the Pro-FEIBA Study Clinical Results >>

The results are in

In the Pro-FEIBA study (n=26), FEIBA prophylaxis showed a significant reduction in the frequency of bleeding events in severe haemophilia A patients with FVIII inhibitors Read more


Visit Haemophilia to read the PROOF Study and access to more articles related to managing haemophilia patients with inhibitors. Read more

Sustained activity

FEIBA offers a long dosing interval. Read more

Demonstrated efficacy in prophylaxis

Learn how FEIBA prophylaxis can reduce bleed frequency and preserve joints. Read more

Dosing FEIBA

Learn how to dose FEIBA. Read more